

Dr. Jeannie Hoffman-Censits
Medical Oncologist
2 Podcasts • 4 Cases • 1 Course on BackTable
Dr. Jeannie Hoffman-Censits is a medical oncologist at Johns Hopkins in Baltimore, Maryland.
Learn from the experiences and expertise of Dr. Jeannie Hoffman-Censits and other leading voices in your specialty on the BackTable app.

Episode # 16 • 27 May 2025
Insights on Management of Upper Tract Urothelial Cancer
With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC).
This podcast is supported by:
More from Dr. Jeannie Hoffman-Censits
Loading recent podcasts…
Urology Case
Jun 24, 2025
UTUC: Recurring Low-Grade UTUC In 66-year Old
Urology Case
Jun 24, 2025
UTUC: 57-year Old with High-Grade Recurrent Urothelial Cancer in Solitary Kidney
Urology Case
Jun 24, 2025
UTUC: 73-year Old Man with High-Grade Urothelial Carcinoma of the Ureter
Urology Case
Jun 24, 2025
UTUC: 55-year Old Female with Upper Tract Urothelial Cancer
About
Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine.
Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018.
Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.